Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Phase II study of teniposide in adenocarcinoma of the lung


A total of 26 evaluable patients with previously untreated, non-resectable adenocarcinoma of the lung were given 80 mg/m2 i.v. teniposide daily for 5 days every 3 weeks. Three partial responses (11%) were obtained that lasted for 12, 11 and 32 weeks, respectively. Leucopenia was the dose-limiting side effect, with WBC counts of <2×109/l being observed in 42% of patients, resulting in one septic death. At the dose and schedule used in the present study, teniposide showed only limited activity in adenocarcinoma of the lung.

This is a preview of subscription content, log in to check access.


  1. 1.

    Bhuchar VK, Boyle LE, Lanzotti VJ (1978) VM-26 in non-oat-cell bronchogenic carcinoma. Proc Am Assoc Cancer Res ASCO 19: 407

  2. 2.

    Creech RH, Mehta CR, Cohen M, Donovan M, Sponzo R, Mason BA, Skeel RT, Ahmed F, Creaven PJ, Lerner HJ, Foelsch E (1981) Results of a phase II protocol for evaluation of new chemotherapeutic regimens in patients with inoperable non-small-cell lung carcinoma (EST-2575, generation 1). Cancer Treat Rep 65: 431–438

  3. 3.

    Eagan RT, Frytak S, Creagan ET, Richardson RL, Coles DT, Jett JR (1986) Differing response rates and survival between squamous and non-squamous non-small-cell lung cancer. Am J Clin Oncol 9: 249–254

  4. 4.

    Finkelstein DM, Ettinger DS, Ruckdeschel JC (1986) Long-term survivors in metastatic non-small-cell lung cancer: an Eastern Cooperative Oncology Group study. J Clin Oncol 4: 702–709

  5. 5.

    Giaccone G, Donadio M, Ferrati P, Bonardi G, Ciuffreda L, Bagatella M, Calciati A (1987) Teniposide in the treatment of non-small-cell lung carcinoma. Cancer Treat Rep 71: 83–85

  6. 6.

    Madejewicz S, West CR, Park HD (1981) Phase II study of intraarterial 4′-0-demethyl-1-0(4,6-0-2-thenylidene-β-d-glucopyranosyl) epipodophyllotoxin (VM-26) therapy of metastatic bronchogenic adenocarcinoma of the brain. Proc Am Assoc Cancer Res/ASCO 22: 502

  7. 7.

    Maroun JA, Stewart DJ, Young V, Belanger R, Crook AF (1982) Effectiveness of VM-26 in non-small-cell carcinoma of the lung (NSCLC) with cerebral nervous system (CNS) metastases. Preliminary results. Proc ASCO 1: 140

  8. 8.

    Rapp E, Pater JL, Willan A, Cormier Y, Murray N, Ewans WK, Hodson DI, Clark DA, Feld R, Arnold AM, Ayoub JI, Wilson KS, Latreille J, Wierzbicki RF, Hill DP (1988) Chemotherapy can prolong survival in patients with advanced non-small-cell lung cancer. Report of a Canadian multicenter randomized trial. J Clin Oncol 6: 633–641

  9. 9.

    Samson MK, Baker LH, Talley RW, Fraile RJ (1978) VM-26 (NSL-122819): a clinical study in advanced cancer of the lung and ovary. Eur J Cancer 14: 1395–1399

  10. 10.

    Sørensen JB, Hansen HH (1988) Combination chemotherapy for advanced adenocarcinoma of the lung. Cancer Chemother Pharmacol 21: 103–116

  11. 11.

    Sørensen JB, Clerici M, Hansen HH (1988) Single-agent chemotherapy for advanced adenocarcinoma of the lung. A review. Cancer Chemother Pharmacol 21: 89–102

  12. 12.

    Sørensen JB, Badsberg JM, Olsen JE (1989) Prognostic factors in inoperable adenocarcinoma of the lung: a multivariate analysis of 259 consecutive patients. Cancer Res 49: 5748–5754

  13. 13.

    Watkin SW (1989) Temporal demographic and epidemiological variation in histologic subtypes of lung cancer: a literature review. Lung Cancer 5: 69–81

  14. 14.

    World Health Organization (1979) Handbook for reporting results of cancer treatment. Offset publication 42. WHO, Geneva

Download references

Author information

Correspondence to Jens Benn Sørensen.

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Sørensen, J.B., Bach, F., Dombernowsky, P. et al. Phase II study of teniposide in adenocarcinoma of the lung. Cancer Chemother. Pharmacol. 27, 487–489 (1991).

Download citation


  • Adenocarcinoma
  • Cancer Research
  • Partial Response
  • Evaluable Patient
  • Limited Activity